Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. Peloton is initially targeting HIF-2α, a transcription factor which was previously thought to be intractable using a small molecule. The company is a leader in the field of HIF-2α biology and pioneered the first HIF-2α to enter into clinical development.
Translating Novel Scientific Insights Into First-In-Class Medicines
Our drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches.